LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

研究发现早期肺癌的蛋白生物标志物

By LabMedica International staff writers
Posted on 05 Jun 2018
Print article
图片:Genepix 4000B微阵列扫描仪(图片蒙分子器件公司惠赐)。
图片:Genepix 4000B微阵列扫描仪(图片蒙分子器件公司惠赐)。
美国癌症学会(ACS)估计,2018年美国有154,050人将死于肺癌,世界卫生组织(WHO)表示,全世界有169万例肺癌死亡。
 
大多数肺癌初次确诊时已到晚期,所以肺癌与预后不良相关,是世界范围内癌症相关死亡的首要原因。因此,在可行切除术的早期阶段发现癌症患者极端重要。
 
日本神奈川县北里大学联合医学科学学院(www.kitasato-u.ac.jp)的科学家获得了冷冻的新鲜肺癌组织,并在用于蛋白质组学分析前储藏在-80 °C下。用271名肺癌患者和100名健康对照的血清作为训练集。此外,验证集包括100名肺癌患者和38名健康对照的血清。
 
科研小组开发了单克隆抗体来确证他们的研究。他们还进行了免疫印迹分析,用美国马萨诸塞州伯灵顿市默克公司(www.merckmillipore.com)的Immobilon Western化学发光HRP底物检测膜上的免疫反应带,再用日本东京ATTO公司(www.atto.co.jp)的Cool Saver系统捕获免疫反应带。科研小组还进行了免疫组化染色,在美国加利福尼亚州森尼韦尔市分子器件公司(www.moleculardevices.com)的Genepix 4000B微阵列扫描仪上扫描染色后的涂片,做反相蛋白质阵列(RPPA)分析。
 
在生成的单克隆抗体中,一种命名为KU-Lu-1的抗体识别出细胞骨架相关蛋白4 (CKAP4)。肺癌细胞和组织中检测到CKAP4,还证实它排入培养液的上清液。肺癌患者血清中的CKAP4水平显著高于健康对照者。再者,I期腺癌或鳞状细胞癌患者血清中的CKAP4水平也高于健康对照者。血清CKAP4水平也许能区分肺癌患者与健康对照者,可以在早期检测到,甚至是I期非小细胞肺癌患者。验证集肺癌患者血清中的CKAP4水平也显著高于健康对照者。
 
该研究的论文发表于2018年5月8日的《美国病理学杂志》(The American Journal of Pathology)。资深作者、分子诊断学教授佐藤裕一博士说:“用CKAP4作为生物标志物能改变对肺癌患者的现行治疗惯例,联用CKAP4与常规标志物也许能明显提高诊断准确度。”
 
Related Links:

北里大学联合医学科学学院>>> www.kitasato-u.ac.jp

默克 >>> www.merckmillipore.com

ATTO >>> www.atto.co.jp

分子器件公司>>> www.moleculardevices.com


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more